在孕期糖尿病中通过持续的葡萄糖监测优化术后血糖控制:两种系统的可行性和比较分析:试点研究
相关实验视频
Updated: Jan 16, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
Joanna Kacperczyk-Bartnik1, Aleksandra Urban1, Paweł Bartnik1
1II Department of Obstetrics and Gynecology, Medical University of Warsaw, 02-091 Warsaw, Poland.
Journal of clinical medicine
|September 27, 2025
概括
持续的葡萄糖监测 (CGM) 是可靠的在剖腹产期间,孕期糖尿病患者 (PGDM). 这项研究表明,CGM系统的性能很好,支持其在产科外科护理中的使用.
科学领域:
- 内分泌学 在内分泌学.
- 产科 产科 产科 产科 产科
- 医疗器械 医疗器械
背景情况:
- 持续的葡萄糖监测 (CGM) 对于管理妊娠糖尿病至关重要.
- 它在剖腹产期间的使用尚未得到充分记录.
- 本研究评估了在剖腹产分娩背景下CGM的可行性.
研究的目的:
- 评估 FreeStyle Libre 2 和 Medtronic Guardian Connect CGM 系统的性能和可靠性.
- 在孕期糖尿病患者的剖腹产和产后早期评估CGM的实用性.
主要方法:
- 展望性,单一患者可行性研究.
- 通过两个CGM系统持续监测手术前18小时到产后5天.
- 评估葡萄糖数据,设备性能和可用性.
主要成果:
- 这两种CGM系统在整个外科手术期间都提供了不间断的高质量数据.
- 在麻醉和手术期间,没有发生传感器移位或信号损失.
- 血糖读数稳定,在麻醉开始时略有升高,术后趋势相似.
结论:
- 对于接受剖腹产的PGDM患者来说,CGM是可行的和可靠的.
- 研究结果支持将CGM纳入产科外科护理.
- 需要进行更大规模的研究来证实临床益处.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Pathophysiology of Diabetes
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Glucose Homeostasis: Regulation of Blood Glucose
3.9K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.9K
Hypoglycemia and Glucagon
835
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
835
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600

